User account menu Search Menu Home Investors Novartis Financial Data Novartis Quarterly Financial Results Novartis Quarterly Financial Results Q3 2021 Q2 2021 Q1 2021 Annual results and Q4 2020 Archive Q3 2021 results - Tuesday, October 26, 2021 Media release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.4 MB) Interim financial report (PDF 0.5 MB) Watch the webcast Download the podcast (MP3 43 MB) Read the presentation transcript Download the presentation (PDF 9.7 MB) Novartis ESG Update - October 27, 2021 (PDF 0.5 MB) Key figures1 Q3 2021 (USD m) Q3 2020 (USD m) % change (USD/cc) Net sales 13,030 12,259 6 (cc: 5) Operating income 3,233 2,412 34 (cc: 32) Net income 2,758 1,932 43 (cc: 41) EPS (USD) 1.23 0.85 45 (cc: 44) Free cash flow 4,423 2,697 64 Core Operating income 4,467 4,069 10 (cc: 9) Net income 3,830 3,467 10 (cc: 9) EPS (USD) 1.71 1.52 13 (cc: 11) Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 47 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Novartis Navigate Patients and Caregivers Healthcare Professionals Researchers Job Seekers Journalists Investors Partners Suppliers Topics Clinical Trials COVID-19 Info Center ESG Explore Stories Diseases Locations Companies Sandoz Advanced Accelerator Applications Footer Bottom © 2021 Novartis AG Terms of Use Privacy Contacts Cookie Settings Site Map Novartis Site Directory This site is intended for a global audience